Keywords: Affymax, Takeda, Peginesatide, NDA, USA, Renal failure, Patent, Johnson & Johnson, Hematide

Affymax and Takeda file peginesatide NDA for anemia associated with chronic renal failure in dialysis patients

Article | 01 June 2011

Print This

USA-based Affymax (Nasdaq: AFFY) and Japan’s largest drugmaker, Takeda Pharmaceutical (TSE: 4502) have filed a New Drug Application with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in